Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a fully integrated biopharmaceutical company. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical and regulatory activities to support... see more

Recent & Breaking News (NDAQ:AUPH)

Aurinia Presents Voclosporin Efficacy and Pharmacokinetic Data from Integrated Analysis of AURA-LV and AURORA Pivotal Trials at ASN Kidney Week 2020

Business Wire October 22, 2020

Aurinia Pharmaceuticals Announces Launch of Lupus Nephritis Disease-State Awareness Initiative for Healthcare Professionals, TimeIsNephrons.com

Business Wire October 14, 2020

Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 2, 2020

Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eye Syndrome

Business Wire September 28, 2020

Aurinia Pharmaceuticals to Present at Three Upcoming Virtual Investor Conferences

Business Wire September 10, 2020

Aurinia Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 4, 2020

Aurinia Reports Second Quarter 2020 Financial Results and Recent Operational Highlights

Business Wire August 11, 2020

Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

Business Wire August 4, 2020

Aurinia Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 11, 2020

Business Wire July 30, 2020

Aurinia Closes US$200 Million Public Offering of Common Shares

Business Wire July 27, 2020

Aurinia Prices US$200 Million Public Offering of Common Shares

Business Wire July 22, 2020

Aurinia Announces Public Offering of Common Shares

Business Wire July 22, 2020

Aurinia Announces U.S. Food and Drug Administration Acceptance of the Filing of New Drug Application and Priority Review for Voclosporin for the Treatment of Lupus Nephritis

Business Wire July 21, 2020

Aurinia Completes Patient Enrollment Into the AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome

Business Wire June 22, 2020

S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index and S&P/TSX 60 Index

Canada NewsWire June 12, 2020

Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020

Business Wire June 9, 2020

Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress

Business Wire June 5, 2020

Aurinia Announces Results of Annual General Meeting

Business Wire June 3, 2020

Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Business Wire June 1, 2020

Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis

Business Wire May 26, 2020